Summary: Genmab A/S increases its share capital by 153,363 shares as a result of
employee warrant exercise.
Copenhagen, Denmark; November 5, 2008 - Genmab A/S (OMX: GEN) has decided to
increase its share capital by 153,363 shares as a consequence of the exercise of
employee warrants.
The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following prices per share of nominally DKK 1: 101,750 shares at DKK 86.00,
6,250 shares at DKK 89.50, 12,500 shares at DKK 97.00, 30,050 shares at DKK
101.00, 1,688 shares at DKK 116.00 and 1,125 shares at DKK 224.00. Proceeds to
the company are approx. DKK 14 million (approx. USD 2.4 million). The increase
corresponds to approx. 0.34 % of the company's share capital.
The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company as of subscription, i.e.
inter alia full rights to dividends for the financial year 2008. The new shares
will be listed on the OMX Nordic Exchange Copenhagen A/S after registration with
the Danish Commerce and Companies Agency. Genmab A/S' current share capital
amounts to DKK 44,735,466 and will after the capital increase be DKK 44,888,829.
The capital increase is expected to be finalized shortly.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery, development and manufacturing teams are using
cutting-edge technology to create and develop products to address unmet medical
needs. Our primary goal is to improve the lives of patients who are in urgent
need of new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. For a
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on www.genmab.com. Genmab does
not undertake any obligation to update or revise forward looking statements in
this press release nor to confirm such statements in relation to actual results,
unless required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM)
and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Investor News No. 52/2008
###
